CDK4 and sarcoma: The herein applied OV XVir-N-31 is soon to be tested in a combination therapy with CDK4/6 inhibition in phase 1 clinical trials for pediatric sarcoma, hence the assessment of additional combinations including XVir-N-31 and other immune activating agents is obvious.